ArticleCell communication and signaling : CCS2025
CHI3L1 promotes cell division through activation of RhoA in lung cancer cells.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundCytokinesis, the final stage of cell division, is crucial for maintaining genomic stability. Dysregulation of cytokinesis can contribute to cancer development. This study aimed to investigate the role of CHI3L1 in cytokinesis and its influence on lung cancer cell growth.
methodsWe modulated CHI3L1 expression in lung cancer cells (overexpression and depletion) and normal cells, assessing effects on cytokinesis, mitotic duration, and actomyosin ring formation. In vivo studies were conducted using CHI3L1 knockout mice with tumor xenografts. Expression and activity of RhoA and Ect2 were analyzed using immunoblotting and immunohistochemistry.
resultsCHI3L1 overexpression in lung cancer cells accelerated cytokinesis, shortened mitosis, and enhanced cell proliferation. Conversely, CHI3L1 depletion in A549 cells increased multinucleation, impaired furrow formation, prolonged mitosis, and caused abnormal cytokinesis. Normal cells were less affected by CHI3L1 modulation. Mechanistically, CHI3L1 promoted formation and contraction of the actomyosin ring via RhoA and Ect2, effects more pronounced in cancer cells. In CHI3L1 knockout mice, tumor tissues exhibited reduced RhoA activity and Ect2 expression.
conclusionsCHI3L1 functions as a novel regulator of cytokinesis, promoting actomyosin ring formation and efficient mitosis, particularly in cancer cells. Its elevated expression in NSCLC and its influence on RhoA and Ect2 suggest that CHI3L1 may serve as a potential therapeutic target for disrupting aberrant cytokinesis in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.